- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharmaceuticals Inc stock price live, this page displays NASDAQ VRTX stock exchange data. View the VRTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vertex Pharmaceuticals Inc real time stock price chart below.
What Is the Vertex Pharmaceuticals Inc Stock Price Today?
The Vertex Pharmaceuticals Inc stock price today is 434.38.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc?
The stock ticker symbol for Vertex Pharmaceuticals Inc is VRTX.
Is VRTX the Same as $VRTX?
$VRTX is a common way to refer to the Vertex Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Vertex Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX quote. (ISIN: US92532F1003)
What Is the Vertex Pharmaceuticals Inc Stock Price Today?
The Vertex Pharmaceuticals Inc stock price today is 434.38.
What Is the Stock Symbol for Vertex Pharmaceuticals Inc?
The stock ticker symbol for Vertex Pharmaceuticals Inc is VRTX.
Is VRTX the Same as $VRTX?
$VRTX is a common way to refer to the Vertex Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Vertex Pharmaceuticals Inc Trade On?
Vertex Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Vertex Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Vertex Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Vertex Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRTX quote. (ISIN: US92532F1003)
434.64
+1.10(+0.25%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
433.39
438.84
52 wk Range
362.50
507.92
VRTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
433.39438.84
52 wk Range
362.50507.92
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VRTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
548.10
Upside
+26.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
9 analysts have revised their earnings downwards for the upcoming period
- Why is Vertex Pharmaceuticals stock rallying today?
- Investing.com
- Vertex Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 VERTEX PHARMACEUTICALS INC / MA For: 15 May
- Investing.com
- Vertex Pharm receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 VERTEX PHARMACEUTICALS INC / MA For: 15 May
- Investing.com
- Form 6K Vertex Pharmaceuticals Inc For: 15 May
- Investing.com
- Form 144 VERTEX PHARMACEUTICALS INC / MA For: 12 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
27 Buy
5 Hold
1 Sell
Ratings:
33 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 548.10
(+26.11% Upside)
Vertex Pharmaceuticals Inc SWOT Analysis
Competitive Dynamics | Vertex faces competition from VERA's atacicept, already at BLA stage, creating pressure to demonstrate superior efficacy and capture market share quickly |
Market Opportunity | The kidney disease franchise targets a multi-billion-dollar market across IgAN and PMN indications, with potential for first-in-class designation |
Analyst Perspectives | Average price target stands at $446, with ratings ranging from Equal Weight to Buy, reflecting divergent views on execution risk versus franchise potential |
Kidney Drug Promise | Povetacicept achieved 64% reduction in key kidney disease markers through dual BAFF/APRIL blockade, surpassing single-pathway competitors |
Vertex Pharmaceuticals Inc Earnings Call Summary for Q1/2026
- Q1 2026 EPS of $4.47 beat estimates by 3.23%, though revenue of $2.99B missed forecasts by 1.32%, growing 8% year-over-year.
- Operating income rose 11% to $1.31B; company maintains strong balance sheet with $13B in cash and investments.
- New products CASGEVY and JOURNAVX drove growth alongside CF portfolio; executives emphasized continued innovation and market expansion.
- Company projects Q2 2026 EPS of $4.75 and FY 2026 revenue of $13.02B, though 10 analysts revised earnings downward for upcoming period.
- Stock rose 0.1% aftermarket to $424.02; VX-522 program discontinued due to patient safety concerns, focus shifting to alternative solutions.
Last Updated: 05/04/2026, 05:59 PM
Read Full TranscriptVertex investor slides for Q1/2026
Last Update: May 04, 2026
See full investor slides
Earnings
Latest Release
May 04, 2026
EPS / Forecast
4.47 / 4.33
Revenue / Forecast
2.99B / 3.03B
Compare VRTX to Peers and Sector
Metrics to compare | VRTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.4x | 22.1x | −0.5x | |
PEG Ratio | 0.05 | 0.01 | 0.00 | |
Price / Book | 5.7x | 4.6x | 2.6x | |
Price / LTM Sales | 9.0x | 2.7x | 3.1x | |
Upside (Analyst Target) | 28.9% | 0.0% | 53.0% | |
Fair Value Upside | Unlock | 9.2% | 6.3% | Unlock |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vertex (VRTX) Stock Price Today?
The Vertex stock price today is 434.64 USD.
What Stock Exchange Does Vertex Trade On?
Vertex is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vertex?
The stock symbol for Vertex is "VRTX."
What Is the Vertex Market Cap?
As of today, Vertex market cap is 110.20B USD.
What Is Vertex's Earnings Per Share (TTM)?
The Vertex EPS (TTM) is 16.86.
When Is the Next Vertex Earnings Date?
Vertex will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is VRTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Vertex Stock Split?
Vertex has split 1 times.
How Many Employees Does Vertex Have?
Vertex has 6400 employees.
What is the current trading status of Vertex (VRTX)?
As of May 22, 2026, Vertex (VRTX) is trading at a price of 434.64 USD, with a previous close of 433.54 USD. The stock has fluctuated within a day range of 433.39 USD to 438.84 USD, while its 52-week range spans from 362.50 USD to 507.92 USD.
What Is Vertex (VRTX) Price Target According to Analysts?
The average 12-month price target for Vertex is 548.10 USD, with a high estimate of 641 USD and a low estimate of 330 USD. 27 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +26.11% Upside potential.
What Is the VRTX Premarket Price?
VRTX's last pre-market stock price is 433.85 USD. The pre-market share volume is 750.00, and the stock has decreased by 0.31, or 0.07%.
What Is the VRTX After Hours Price?
VRTX's last after hours stock price is 433.95 USD, the stock has decreased by 0.41, or 0.09%.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.